72 related articles for article (PubMed ID: 3260565)
1. Generation of LAK cells depends on the age of LAK cell precursor donors.
Indrová M; Bubeník J
Folia Biol (Praha); 1988; 34(1):48-52. PubMed ID: 3260565
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
3. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
4. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
Gregg EO; Gregg IC; Green I
Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
[TBL] [Abstract][Full Text] [Related]
5. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
Brooks B; Rees RC
Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652
[TBL] [Abstract][Full Text] [Related]
6. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
Espevik T; Figari IS; Ranges GE; Palladino MA
J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
[TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of cytotoxic granules from human lymphokine (interleukin 2) activated killer cells.
Lowrey DM; Hameed A; Lichtenheld M; Podack ER
Cancer Res; 1988 Aug; 48(16):4681-8. PubMed ID: 3260817
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of murine sarcomas with interleukin 2. II. Activation of killer cells by human recombinant IL-2.
Indrová M; Bubeník J; Toulcová A
Folia Biol (Praha); 1986; 32(6):392-8. PubMed ID: 3492397
[TBL] [Abstract][Full Text] [Related]
10. Strain- and age-dependent natural and activated in vitro cytotoxicity in athymic nude mice.
Radzikowski C; Rygaard J; Budzynski W; Stenvang JP; Schou M; Vangsted A; Zeuthen J
APMIS; 1994 Jul; 102(7):481-8. PubMed ID: 7917216
[TBL] [Abstract][Full Text] [Related]
11. [The in vitro antitumor effectiveness of murine lymphokine-activated killer (LAK) cells induced by recombinant IL-2].
Okamoto Y; Shimizu K; Miyao Y; Ushio Y; Matsui Y; Hayakawa T; Tsuda N; Mogami H
No To Shinkei; 1986 Mar; 38(3):233-7. PubMed ID: 3486667
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer cells: culture conditions for the generation of maximal in vitro cytotoxicity in cells from normal donors.
Beckner SK; Maluish AE; Longo DL
Cancer Res; 1987 Oct; 47(20):5504-8. PubMed ID: 3498534
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
14. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
15. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer (LAK) cells. III. Characterization of LAK precursors and susceptible target cells within the murine thymus.
Ballas ZK; Rasmussen W
J Immunol; 1987 Nov; 139(10):3542-9. PubMed ID: 3500221
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
[TBL] [Abstract][Full Text] [Related]
19. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
20. The precursor cells of mouse lymphokine-activated killer (LAK) cells.
Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y
Thymus; 1987; 9(3):131-9. PubMed ID: 3495912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
